Skip to main content
. 2019 Jan 10;14:536–549. doi: 10.1016/j.omtn.2019.01.002

Figure 2.

Figure 2

miR-672-5p Treatment Restores Ovariectomy-Induced Trabecular Bone Loss in Tibia Bones

(A) Schematic diagram illustrating in vivo experimental setup. (B) Enhanced miR-672-5p expression (qPCR, in triplicate) in bone following injection of a mimic of miR-672-5p using Invivofectamine 3.0 reagent into 12-week-old female BALB/c mice at the end of 6 weeks of treatment, and this indicates sufficient tissue uptake. Data are mean ± SE. ***p < 0.001 compared with the PBS-treated group. (C) Representative 3D images of the tibia bones generated by micro-CT. (D) Volumetric bone-mineral density (vBMD) in the tibia at the end of 6 weeks of treatment was improved. Data are mean ± SE. **p < 0.01 and ***p < 0.001 compared with the PBS-treated group, or as shown ˆˆp < 0.01; n ≥ 6 mice per group. (E) Structural micro-CT parameters for trabecular bone, including BV/TV, Tb.Sp, Tb.N, Tb.Pf, SMI, and Conn.Dn (units are shown) in the tibia epiphyses. Data are mean ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the PBS-treated group, or as shown ˆˆˆp < 0.001; n = 8 mice per group. See also Figure S1 and Table 1 for femur and vertebrae, respectively.